Skip to main content

The RheumNow Week in Review - 26 May 2017

May 26, 2017 1:12 pm

Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:

  1. Study of 24 erosive RA pts shows addition of anabolic teriparatide did not significantly reduce the rate/volume of erosions http://buff.ly/2rh1hsO
  2. Swedish study 27k+ AS, PsA and uSpA are at increased risk for Acute Coronary syndrome & stroke events https://t.co/Zq49quPo3T
  3. β-Defensin2 is a biomarker reflects IL-17A-driven skin dz in psoriasis, not PsA. Highly correlates w/ PASI & IL-17A https://t.co/JmCmMIN0Cq  Study of 8 pts controls the expression of 170 proteins in blood, nonlesional skin, and lesional skin
  4. Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
  5. Claims data on 2495 JIA pts shows significantly more serious bacterial infx w/ TNFi use (HR 2.72) compared to DMARDs https://t.co/CKu9oIOzlj
  6. Among 323 ANCA-Assoc Vasculitis pts, CTX Rx(SIR 3.1) had 4.6 more cancers than RTX (SIR 0.67); RTX = pop Cancer rate https://t.co/NZnCbMOGQt
  7. Kevzara (Sarilumab) the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
  8. FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis, based on GiACTA study. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL   PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
  9. ACR supports FDA draft on interchangeability, naming suffixes & Biosimilar User Fee Act; but not extrapolation- huh? https://t.co/5aKzmwul2N
  10. Survey of 364 UK RA pts shows that giving info on TNFi helps 1/3 and scares 1/3. Many misconceptions about safety https://t.co/lM8gxjjulk
  11. Dr Erkan says secondary THROMBOSIS prevention- Venous-rx warfarin keep INR 2-3; Arterial - warfarin keep INR 2-3 + ASA, or INR 3-4 w/o ASA
  12. Dr Forum Erkan says catastrophic antiphospholipid syndrome should be Rx with anticoagulation, steroids, IVIG w/ plasma exchange (+/- RTX)
  13. Anti-Sclerostin Drug -Romosozumab (EVENITY) Hampered by Heart Problems 
  14. Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis  
  15. NLRP3 Activation in Still's Disease 
Disclosures
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×